Search

Displaying results 3611 - 3620 of 10000 in total
  1. Drug

    Phendimetrazine

    go.drugbank.com/drugs/DB01579
    ApprovedIllicit

    Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.

    Synonyms: (2S,3S)-3,4-dimethyl-2-phenylmorpholine
  2. Drug

    Zavacorilant

    go.drugbank.com/drugs/DB21509
    Investigational

    Zavacorilant is a small molecule drug. The usage of the INN stem '-corilant' in the name indicates that Zavacorilant is a glucocorticoid receptor antagonist (non-steroidal). … Zavacorilant is under investigation in clinical trial NCT04672512 (Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants).

  3. Drug

    Neladalkib

    go.drugbank.com/drugs/DB21712
    Investigational

    Neladalkib is a small molecule drug. The usage of the INN stem '-alkib' in the name indicates that Neladalkib is a ALK (anaplastic lymphoma kinase) inhibitor. … Neladalkib is under investigation in clinical trial NCT06765109 (Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC).

  4. Drug

    Xiliertinib

    go.drugbank.com/drugs/DB21453
    Investigational

    Xiliertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Xiliertinib is a epidermal growth factor receptor (EGFR) inhibitor. … Xiliertinib is under investigation in clinical trial NCT02601274 (Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor). Xiliertinib has a monoisotopic molecular weight of 442.21 Da.

  5. Drug

    Paltimatrectinib

    go.drugbank.com/drugs/DB21588
    Investigational

    Paltimatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Paltimatrectinib is a tropomyosin receptor kinase (TRK) inhibitor. … Paltimatrectinib is under investigation in clinical trial NCT04901806 (Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors).

  6. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    [L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission … [A244920] The ossification occurring as a result of FOP is insidious and cumulative and is provoked during flare-ups or in response to injury.

  7. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.

  8. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    [A18262] Use of non-stimulant medications such as atomoxetine is therefore thought to offer a clinical advantage over the use of traditional medications for the management of ADHD. … is a limiting factor associated with the use of stimulant medications such as [DB00422], [DB01576], and [DB01255].

  9. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive … Deutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator.

  10. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran]. … [A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated.